Indications for use of recombinant factor VIIa: a case study with implications for research.
The purpose of this case study was to explore the current use of recombinant factor VIIa to control hemorrhage in the trauma patient. Despite aggressive blood product replacement and surgical intervention, uncontrolled bleeding and resultant coagulopathy are lethal to the trauma patient. What is the correlation between this drug and the hemorrhagic trauma patient? Quite simply--does it work? Curiosity may have killed the cat, but this case study clearly demonstrates the need for further research and satisfactory answers to questions illuminated by this case.
Moeller
Marylou S
MS
New Hanover Regional Medical Center, Wilmington, NC 28402, USA. marylou.moeller@nhhn.org
D000063:Accidents, Traffic; D004334:Drug Administration Schedule; D004632:Emergency Medical Services / Q000379:methods / Q000592:standards; D004638:Emergency Treatment / Q000379:methods / Q000592:standards; D019317:Evidence-Based Medicine; D005167:Factor VII / Q000494:pharmacology / Q000627:therapeutic use*; D015942:Factor VIIa; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D009049:Motorcycles; D009104:Multiple Trauma / Q000150:complications*; D009657:North Carolina; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013997:Time Factors; D014193:Trauma Centers; D016896:Treatment Outcome
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa